- GlobeNewswire•yesterdayCombiMatrix to Present Large-Scale Study Indicating the Severity of Genomic Abnormalities Decreases from Conception to Childhood at the 2nd Congress on Recurrent Pregnancy Loss
IRVINE, Calif., Jan. 20, 2017-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that results ...
- GlobeNewswire•2 months agoCombiMatrix’s Pre-Implantation Genetic Screening by Next Generation Sequencing Granted Conditional Approval from New York State Department of Health
IRVINE, Calif., Nov. 29, 2016-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that its pre-implantation ...
- Zacks Small Cap Research•2 months ago
Déjà vu, except even better. CombiMatrix (CBMX) reported financial results for the third quarter ending September 30th. Not only was this the sixth straight quarter of improving profitability but sequential operating loss fell by an impressive 31%, from $1.2M in Q2 2016 to just $846k in Q3, marking the first time that operating loss fell below the $1M mark. Management has done a noteworthy job of growing the top line through a combination of test volume growth, expansion of the customer base (to a current record of 257), improved cash collections and higher average test pricing (or reimbursement). But, in our opinion, what is even more impressive is that they’ve done so while also shedding expenses and improving margins. The result has been revenue growing 26% yoy through the first nine months of 2016 (including 29% in Q3) and average gross margin and operating loss improving from 45.6% and $4.9M to 53.6% and $3.5M over the same period.
CBMX : Summary for CombiMatrix Corporation - Yahoo Finance
CombiMatrix Corporation (CBMX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.05 x 1100|
|Ask||3.25 x 300|
|Day's Range||3.05 - 3.45|
|52 Week Range||2.15 - 7.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.59|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|